XPhyto Therapeutics Corp.
4XT.DE
Get informed when a big investor buys or sells
+ FollowMarket Cap$42.25M
Close$
Share Statistics
| Market cap | $42.25 Million |
|---|---|
| Enterprise Value | $47.73 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.19 |
| Beta | 0.15 |
| Outstanding Shares | 82,297,299 |
Return
| Return on Equity | 146.16% |
|---|---|
| Return on Assets | -591.08% |
| Return on Invested Capital | 160.69% |
Valuation & Multiples
| P/E Ratio | -4.4 |
|---|---|
| PEG | 36.87 |
| Price to Sales | - |
| Price to Book Ratio | -0.37 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -5.79 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | -1.07 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About BioNxt Solutions Inc.
25 employees
CEO: Hugh A. D. Rogers Headquartered in Vancouver, Canada, BioNxt Solutions Inc., established in 2017, operates as a bioscience company across Germany, Switzerland, Austria, Israel, and its home country. The firm focuses on developing innovative drug delivery ...